(IN BRIEF) The DANISH-CRT trial, presented at ESC Congress 2026 in Munich and published simultaneously in The Lancet, found that targeted placement of the left ventricular lead did not improve outcomes compared with standard placement in patients with heart failure … Read the full press release
Posted in Business, Denmark, Education, France, Germany, Healthcare, Science, Technology
Tagged 000 patients, 1, 25.5%, 27.9%, 31 August 2026, 45.8 months median follow-up, 95% confidence interval, Aarhus University Hospital, biventricular pacing, cardiac resynchronisation therapy, cardiovascular medicine, conduction abnormalities, coronary sinus branches, CRT, Danish Heart Foundation, Danish Pacemaker and ICD Registry, DANISH-CRT, Death, Denmark, double-blind trial, electrical mapping, ESC, ESC Congress 2026, ESC Hot Line Trial Questions Routine Electrical Mapping for CRT Lead Placement, European Society of Cardiology, functional status, hazard ratio 1.10, heart failure, heart failure hospitalisation, Hot Line 10, Hot Line session, Independent Research Fund Denmark, investigator-initiated trial, latest electrical activation, LBBB, lead-related complications, left bundle branch block, left ventricular lead placement, left ventricular structural changes, Messe München GmbH, Munich, non-apical coronary sinus, Novo Nordisk Foundation, p value 0.45, pacemaker treatment, physical capacity, posterolateral coronary sinus, primary endpoint, Professor Jens Cosedis Nielsen, quality of life, randomised controlled trial, secondary endpoints, standard lead placement, targeted lead placement, Targeted Left Ventricular Lead Placement Fails to Improve CRT Outcomes in Danish Trial, The Lancet, The Lancet Publishes DANISH-CRT Results on Cardiac Resynchronisation Therapy Lead Placement, unplanned hospitalisation
(IN BRIEF) A large UK clinical trial involving the University of Liverpool and the University of Oxford has found that most children with severely broken wrists can be successfully treated without surgery. The CRAFFT trial showed that while surgery may … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Marketing, Science, Technology, United Kingdom
Tagged Alder Hey Children’s NHS Foundation Trust, bone remodelling, CRAFFT trial, Dan Perry, healthcare cost savings, Major UK Trial Shows Cast First Approach Can Replace Surgery for Most Childhood Wrist Injuries, Matt Costa, National Institute for Health and Care Research, non surgical treatment, pediatric fractures, pediatric orthopaedics, plaster cast, The Lancet, University of Liverpool, University of Oxford, wrist fractures
(IN BRIEF) AstraZeneca’s Alexion division has received FDA approval for Koselugo (selumetinib) to treat adults with NF1 who have symptomatic, inoperable plexiform neurofibromas. The decision is based on strong results from the Phase III KOMET trial, which showed a 20% … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged adult NF1 PN, Alexion, Annette Bakker, ASCO 2025, AstraZeneca, AstraZeneca Expands Koselugo’s Clinical Reach with New US Approval for Adults Living with Inoperable NF1 Plexiform Neurofibromas, Children’s Tumor Foundation, FDA approval, KOMET Phase III trial, Koselugo, Marc Dunoyer, MEK inhibitor, neurofibromatosis type 1, NF1, paediatric NF1 PN, Pierre Wolkenstein, plexiform neurofibromas, PN, rare disease treatment, regulatory approval, selumetinib, The Lancet, tumour response rate
(IN BRIEF) AstraZeneca’s Alexion has secured European Commission approval for Koselugo (selumetinib), the first targeted therapy available to adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN). The approval is based on the KOMET Phase III trial, … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged adult NF1 treatment, Alexion, American Society of Clinical Oncology, APHP, ASCO 2025, AstraZeneca, AstraZeneca Expands Rare Disease Portfolio with EU Approval of Koselugo for Adults with NF1 Tumours, European Commission approval, European Union, Henri Mondor Hospital, Japan approval, KOMET Phase III trial, Koselugo, Marc Dunoyer, MEK inhibitor, neurofibromatosis type 1, NF1, Paris East University, Pierre Wolkenstein, plexiform neurofibromas, PN, rare disease therapy, selumetinib, The Lancet, tumour response rate, UPEC
(IN BRIEF) A recent comprehensive review published in The Lancet Regional Health Europe offers insights into the risk factors and management strategies for atrial fibrillation (AF), a prevalent heart rhythm disorder affecting millions globally. Conducted by researchers from the University … Read the full press release
Posted in Business, Education, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged atrial fibrillation, Dr Eduard Shantsila, Management, Professor Deirdre Lane, Professor Gregory Lip, risk factors, Seoul National University College of Medicine, The Lancet, University of Liverpool
5-year results of international TARGIT-A clinical trial support targeted intraoperative radiotherapy (TARGIT) delivered with the ZEISS INTRABEAM as non-inferior to external beam radiotherapy (EBRT) for selected early stage breast cancer patients. Jena, Germany, 27-11-2013 — /EuropaWire/ — Results of the TARGIT-A clinical … Read the full press release
Posted in Electronics & Machinery, Germany, Healthcare, Science, Technology
Tagged breast cancer, early stage breast cancer, external beam radiotherapy, new breast cancer clinical trial, post-surgical radiotherapy treatment, Professor Jayant S. Vaidya FRCS MD PhD, Professor Michael Baum, targeted intraoperative radiotherapy, targeted radiotherapy during surgery, TARGIT-A clinical trial, The Lancet, ZEISS, ZEISS INTRABEAM
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?